Expert: UGN-102 has potential to change practice in LG-IR NMIBC
“I think it's extremely exciting to be part of something that is possibly practice changing, potentially field changing,” says Sandip M. Prasad, MD, MPhil.
In this video, Sandip M. Prasad, MD, MPhil, gives his final thoughts on the recent Journal of Urology paper, “Treatment of Low-Grade Intermediate-Risk Nonmuscle-Invasive Bladder Cancer with UGN-102 ± Transurethral Resection of Bladder Tumor (TURBT) Compared to TURBT Monotherapy: A Randomized, Controlled, Phase 3 Trial (ATLAS).” Prasad is a urologist with Garden State Urology in Morristown, New Jersey.
Transcription:
Is there anything you would like to add?
I think this is a very interesting study for urologists as a whole, because there are not many surgical trials that we do. It's a very hard thing to enroll patients into surgical trials. So here, we were actually able to achieve that with randomization, which again, for someone who's been in urology for almost 20 years, surgical trials often don't fill because patients are really reticent to go through a trial that randomizes you to surgery or not surgery. That's a hard decision to leave to the flip of a coin. So I really credit the other study investigators for being able to put patients on study, demonstrating that there's importance for this kind of research. I applaud those other investigators who have been able to enroll patients in a study like this, because in the end, we may have achieved a really paradigm-shifting surgical and medical treatment approach for bladder cancer, which again, is the bread and butter of almost every urology practice. That's the other part of this that's really exciting. It's fun to be part of something that really affects every single urologist from single practitioners in small rural communities, to large academic centers. We're all doing TURBTs; we're all seeing low-grade intermediate-risk bladder cancer. This is an extremely common problem, with tens of thousands of patients that we see a year with this condition who continue to recur over time. And so again, I think it's extremely exciting to be part of something that is possibly practice changing, potentially field changing, and I'm really excited to see what the data from ENVISION show.
This transcript was edited for clarity.
Speaking of Urology Podcast: Dr. Ritch and Dr. Katz discuss new bladder cancer management app
December 7th 2021“It's not a replacement for clinical judgment, obviously. But at the end of the day, the idea is that it shows you what your next steps are based on what the American Urological Association and [Society of Urologic Oncology] guidelines are for non-muscle invasive bladder cancer,” Chad R. Ritch, MD, MBA, FACS.
